The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T.
O'Sullivan C, et al. Among authors: nguyen d.
J Clin Endocrinol Metab. 2014 Apr;99(4):1291-7. doi: 10.1210/jc.2013-2298. Epub 2014 Jan 1.
J Clin Endocrinol Metab. 2014.
PMID: 24423320
Free PMC article.
Clinical Trial.